[Sjögren's syndrome. New diagnostic aspects]

Prior research has shown that Sjögren's syndrome is a complex autoimmune condition with variable clinical presentations. It was already known that diagnosis often occurs after a long latency period due to nonspecific symptoms. No prior work had resolved the full spectrum of symptoms and serological markers in a large patient cohort. This gap motivated the development of new classification criteria to improve diagnostic accuracy. Researchers had previously focused on dry eye and dry mouth as primary indicators, but these are not always present. That uncertainty drove the need to evaluate additional symptoms and biomarkers. Clinical studies had suggested fatigue and joint pain as common features, but their frequency had not been quantified. This paper addresses the lack of comprehensive data on symptom prevalence and antibody associations in primary Sjögren's syndrome.

The aim of this study was to evaluate the clinical and laboratory features of patients classified under new European criteria for Sjögren's syndrome. Researchers sought to understand the diagnostic delay and symptom profile in a cohort of patients. They focused on identifying the most common symptoms beyond dryness of mucous membranes. The study aimed to quantify the frequency of fatigue, arthralgia, and other non-specific symptoms. Researchers also wanted to assess the prevalence of anti-SSA and anti-SSB antibodies. The motivation was to validate the new classification criteria in a real-world patient population. They aimed to determine if these criteria could capture a broader range of clinical features. The study also aimed to explore the association between antibody positivity and adverse pregnancy outcomes.

The study analyzed clinical and laboratory data from 96 patients with primary Sjögren's syndrome. Researchers applied the newly developed European classification criteria to categorize patients. They recorded the latency period from symptom onset to diagnosis for each patient. Symptom prevalence was calculated using patient-reported data and physician assessments. Blood samples were tested for anti-SSA and anti-SSB antibodies using standard immunoassays. Researchers also documented pregnancy outcomes in patients with these antibodies. Data collection included both subjective symptoms and objective findings. Statistical analysis was used to determine the frequency of symptoms and antibody positivity.

The median latency period from symptom onset to diagnosis was 11 years in the study population. Periodic fatigue was reported by 92% of patients as a dominant symptom. Arthralgia was present in 82% of patients, indicating a high prevalence of joint pain. Hoarse voice was observed in 71% of patients, suggesting vocal cord involvement. Dry cough and diarrhea were reported by 54% and 51% of patients, respectively. Anti-SSA antibodies were detected in 22.2% of patients, while anti-SSB antibodies were found in 15.6%. Two out of ten patients with both antibodies had children with heart block. These findings suggest a link between antibody positivity and neonatal complications.

The study highlights the long diagnostic delay and diverse symptom profile in primary Sjögren's syndrome. Researchers found that fatigue and arthralgia are common features beyond dryness of mucous membranes. The presence of anti-SSA and anti-SSB antibodies was confirmed in a significant proportion of patients. The authors suggest that these antibodies may be associated with adverse pregnancy outcomes. The new classification criteria appear to capture a broader range of clinical features. The study supports the use of these criteria for improved diagnostic accuracy. Researchers propose that further studies are needed to confirm the association between antibody positivity and heart block in offspring. The findings may inform future diagnostic guidelines and patient management strategies.